Anal fistula medical therapy: Difference between revisions
Jump to navigation
Jump to search
| Line 5: | Line 5: | ||
==Pharmocotherapy== | ==Pharmocotherapy== | ||
*Empiric therapy for anal fistula depends on [disease factor 1] and [disease factor 2]. | |||
*Empiric therapy for | |||
*Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2]. | *Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2]. | ||
Revision as of 20:31, 25 January 2018
|
Anal fistula Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Anal fistula medical therapy On the Web |
|
American Roentgen Ray Society Images of Anal fistula medical therapy |
|
Risk calculators and risk factors for Anal fistula medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Manpreet Kaur, MD [2]
Overview
Pharmocotherapy
- Empiric therapy for anal fistula depends on [disease factor 1] and [disease factor 2].
- Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].